CA Patent

CA2988373A1 — Nrf2 regulators

Assigned to Astex Therapeutics Ltd · Expires 2016-12-22 · 9y expired

What this patent protects

The present invention relates to aryl analogs Formula (I), pharmaceutical compositions containing them and their use as Nrf2 regulators.

USPTO Abstract

The present invention relates to aryl analogs Formula (I), pharmaceutical compositions containing them and their use as Nrf2 regulators.

Drugs covered by this patent

umeclidinium-bromide (UMECLIDINIUM BROMIDE)

Patent Metadata

Patent number: CA2988373A1
Jurisdiction: CA
Classification: —
Expires: 2016-12-22
Drug substance claim: No
Drug product claim: No
Assignee: Astex Therapeutics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.